标题
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-08-29
DOI
10.3389/fonc.2019.00689
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. BLOOD
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
- (2019) Andrew W. Roberts et al. BLOOD
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MRD negativity as a surrogate for PFS in CLL?
- (2018) Philip A. Thompson BLOOD
- High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies
- (2018) Peter Dreger et al. BLOOD
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
- (2018) Inhye E. Ahn et al. BLOOD
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia
- (2018) Paula Cramer et al. Future Oncology
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
- (2018) Stephan Stilgenbauer et al. LEUKEMIA
- Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
- (2018) Philip A. Thompson et al. LEUKEMIA
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
- (2018) David M. Kurtz et al. JOURNAL OF CLINICAL ONCOLOGY
- Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA
- (2018) Giulia Biancon et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
- (2018) Anton W. Langerak et al. BLOOD
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
- (2018) Julia von Tresckow et al. LEUKEMIA
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
- (2017) Paul Yeh et al. Nature Communications
- Minimal residual disease is an independent predictor for 10-year survival in CLL
- (2016) M. Kwok et al. BLOOD
- Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia
- (2016) Irene Della Starza et al. BRITISH JOURNAL OF HAEMATOLOGY
- Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma
- (2016) Alex F. Herrera et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
- (2016) Gabor Kovacs et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia
- (2016) B Stamatopoulos et al. LEUKEMIA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
- (2015) P. A. Thompson et al. BLOOD
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
- (2015) M. A. Pulsipher et al. BLOOD
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
- (2015) D. Rossi et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma
- (2015) Daniela Drandi et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
- (2015) A C Rawstron et al. LEUKEMIA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
- (2015) T W Farren et al. Blood Cancer Journal
- Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival
- (2014) Aaron C. Logan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
- (2014) P. Strati et al. BLOOD
- Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR
- (2014) Sara Raponi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model
- (2014) T. Baumann et al. HAEMATOLOGICA
- Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
- (2014) J Malcikova et al. LEUKEMIA
- Clinical relevance of circulating cell-free microRNAs in cancer
- (2014) Heidi Schwarzenbach et al. Nature Reviews Clinical Oncology
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Droplet Digital PCR and Seminested Real-Time PCR for Quantification of Cell-Associated HIV-1 RNA
- (2014) Maja Kiselinova et al. PLoS One
- TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
- (2013) P. Dreger et al. BLOOD
- Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
- (2013) P. Abrisqueta et al. BLOOD
- Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
- (2013) Simon E. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics
- (2013) J. F. Huggett et al. CLINICAL CHEMISTRY
- A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia
- (2013) M. M. Sartor et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Clinical implications of the molecular genetics of chronic lymphocytic leukemia
- (2013) R. Foa et al. HAEMATOLOGICA
- Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain react
- (2013) Irene Della Starza et al. HEMATOLOGICAL ONCOLOGY
- Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice
- (2013) O. Stehlíková et al. International Journal of Laboratory Hematology
- Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
- (2013) M Ladetto et al. LEUKEMIA
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
- (2013) A C Logan et al. LEUKEMIA
- Absolute quantification by droplet digital PCR versus analog real-time PCR
- (2013) Christopher M Hindson et al. NATURE METHODS
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2012) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
- (2012) A C Rawstron et al. LEUKEMIA
- ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
- (2012) S Pospisilova et al. LEUKEMIA
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
- (2012) J J M van Dongen et al. LEUKEMIA
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
- (2011) Sebastian Böttcher et al. BLOOD REVIEWS
- A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
- (2011) Peter Hillmen et al. BRITISH JOURNAL OF HAEMATOLOGY
- ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
- (2011) A. Guarini et al. HAEMATOLOGICA
- High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
- (2011) A. C. Logan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
- (2010) P. Dreger et al. BLOOD
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
- (2009) L. Farina et al. HAEMATOLOGICA
- Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
- (2009) S Böttcher et al. LEUKEMIA
- Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Baskar et al. CLINICAL CANCER RESEARCH
- Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
- (2008) M Ritgen et al. LEUKEMIA
- Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
- (2008) Andy C. Rawstron et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started